TY - JOUR
T1 - Accessibility of substituted cysteines in TM2 and TM10 transmembrane segments in the Plasmodium falciparum equilibrative nucleoside transporter PfENT1
AU - Nishtala, Sita Nirupama
AU - Arora, Avish
AU - Reyes, Jorge
AU - Akabas, Myles H.
N1 - Funding Information:
This work was supported by National Institutes of Health Grant R01-AI116665 (to M. H. A.). In 2015, Dr. Akabas received a one-year unrestricted research grant from GlaxoSmithKline (GSK) as part of the GSK Discovery Fast Track Competition to fund the performance of hit validation assays in Dr. Akabas’ laboratory related to the high throughput screen GSK performed with our yeast based assay to identify inhibitors of PfENT1 as potential starting points for the development of novel antimalarial drugs. The only connection between the work supported by GSK and the current work is that they both involve PfENT1. Dr. Akabas holds patents on derivatives of the hits identified by GSK. GSK has no interests in the patents or subsequent work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 2 Supported in part by National Institutes of Health NIGMS Training Program Grant T32 GM007288. We thank Drs. I. J. Frame and Roman Deniskin for advice during the initiation of this project and David Pierce for technical assistance.
Publisher Copyright:
© 2019 Nishtala et al.
PY - 2019/2/8
Y1 - 2019/2/8
N2 - Infection with Plasmodium species parasites causes malaria. Plasmodium parasites are purine auxotrophic. They import purines via an equilibrative nucleoside transporter (ENT). In P. falciparum, the most virulent species, the equilibrative nucleoside transporter 1 (PfENT1) represents the primary purine uptake pathway. This transporter is a potential target for the development of antimalarial drugs. In the absence of a high-resolution structure for either PfENT1 or a homologous ENT, we used the substituted cysteine accessibility method (SCAM) to investigate the membrane-spanning domain structure of PfENT1 to identify potential inhibitor-binding sites. We previously used SCAM to identify water-accessible residues that line the permeation pathway in transmembrane segment 11 (TM11). TM2 and TM10 lie adjacent to TM11 in an ab initio model of a homologous Leishmania donovani nucleoside transporter. To identify TM2 and TM10 residues in PfENT1 that are at least transiently on the water-accessible transporter surface, we assayed the reactivity of single cysteine-substitution mutants with three methanethiosulfonate (MTS) derivatives. Cysteines substituted for 12 of 14 TM2 segment residues reacted with MTS-ethyl-ammonium-biotin (MTSEA-biotin). At eight positions, MTSEA-biotin inhibited transport, and at four positions substrate transport was potentiated. On an helical wheel projection of TM2, the four positions where potentiation occurred were located in a cluster on one side of the helix. In contrast, although MTSEA-biotin inhibited 9 of 10 TM10 cysteine-substituted mutants, the reactive residues did not form a pattern consistent with either an helix or sheet. These results may help identify the binding site(s) of PfENT1 inhibitors.
AB - Infection with Plasmodium species parasites causes malaria. Plasmodium parasites are purine auxotrophic. They import purines via an equilibrative nucleoside transporter (ENT). In P. falciparum, the most virulent species, the equilibrative nucleoside transporter 1 (PfENT1) represents the primary purine uptake pathway. This transporter is a potential target for the development of antimalarial drugs. In the absence of a high-resolution structure for either PfENT1 or a homologous ENT, we used the substituted cysteine accessibility method (SCAM) to investigate the membrane-spanning domain structure of PfENT1 to identify potential inhibitor-binding sites. We previously used SCAM to identify water-accessible residues that line the permeation pathway in transmembrane segment 11 (TM11). TM2 and TM10 lie adjacent to TM11 in an ab initio model of a homologous Leishmania donovani nucleoside transporter. To identify TM2 and TM10 residues in PfENT1 that are at least transiently on the water-accessible transporter surface, we assayed the reactivity of single cysteine-substitution mutants with three methanethiosulfonate (MTS) derivatives. Cysteines substituted for 12 of 14 TM2 segment residues reacted with MTS-ethyl-ammonium-biotin (MTSEA-biotin). At eight positions, MTSEA-biotin inhibited transport, and at four positions substrate transport was potentiated. On an helical wheel projection of TM2, the four positions where potentiation occurred were located in a cluster on one side of the helix. In contrast, although MTSEA-biotin inhibited 9 of 10 TM10 cysteine-substituted mutants, the reactive residues did not form a pattern consistent with either an helix or sheet. These results may help identify the binding site(s) of PfENT1 inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=85061228570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061228570&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA118.006547
DO - 10.1074/jbc.RA118.006547
M3 - Article
C2 - 30541922
AN - SCOPUS:85061228570
SN - 0021-9258
VL - 294
SP - 1924
EP - 1935
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 6
ER -